S. Faderl

发表

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.

D. Berry, E. Estey, J. Wathen, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Haematologica.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

M. Andreeff, H. Kantarjian, J. Cortes, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Staging of chronic myeloid leukemia in the imatinib era

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006, Cancer.

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2014, Leukemia.

Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.

H. Kantarjian, J. Cortes, F. Ravandi, 2011, Clinical lymphoma, myeloma & leukemia.

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Mark Brandt, Susan O'Brien, B Nebiyou Bekele, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014, Leukemia & lymphoma.

Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia

J. Gabrilove, H. Kantarjian, T. Kovacsovics, 2012, Leukemia & lymphoma.

valproic acid in patients with leukemia -deoxycytidine with ' Phase 1/2 study of the combination of 5-aza-2

G. Rosner, E. Estey, Z. Estrov, 2013 .

Phase 2 study of low‐dose clofarabine plus cytarabine for patients with higher‐risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2017, Cancer.

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2009 .

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.

E. Estey, H. Kantarjian, A. Advani, 2009, Blood.

Imatinib front‐line therapy is safe and effective in patients with chronic myelogenous leukemia with pre‐existing liver and/or renal dysfunction

H. Kantarjian, J. Cortes, F. Ravandi, 2010, Cancer.

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

J. Cortes, J. Lancet, G. Uy, 2021, Journal of Hematology & Oncology.

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

E. Estey, M. Andreeff, H. Kantarjian, 2003, Cancer.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012, Blood.

T-cell prolymphocytic leukemia: a single-institution experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2005, Clinical lymphoma & myeloma.

Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.

Z. Estrov, H. Kantarjian, J. Cortes, 2012, Blood.

Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia

J. Byrd, J. Gribben, I. Flinn, 2006, Cancer.

Novel Therapies in Acute Lymphoblastic Leukemia

H. Kantarjian, S. Faderl, 2008 .

Survival benefit with imatinib mesylate therapy in patients with accelerated‐phase chronic myelogenous leukemia—Comparison with historic experience

Susan O'Brien, Jorge Cortes, Guillermo Garcia-Manero, 2005, Cancer.

Outcome of patients with Philadelphia chromosome‐positive chronic myelogenous leukemia post‐imatinib mesylate failure

H. Kantarjian, J. Cortes, S. Verstovsek, 2007, Cancer.

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome‐positive chronic myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.

H. Kantarjian, J. Cortes, M. Talpaz, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abnormal expression of FLI 1 protein is an adverse prognostic factor in acute myeloid leukemia

K. Coombes, Nianxiang Zhang, A. Qutub, 2011 .

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome – positive chronic myeloid leukemia after failure of interferon -

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003 .

Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia

H. Kantarjian, F. Ravandi, S. O'brien, 2008, Cancer.

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.

H. Gundacker, E. Estey, F. Appelbaum, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Cancer.

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Cancer.

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004, Blood.

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004, Blood.

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

P. Sonneveld, H. Kantarjian, G. Martinelli, 2011, Blood.

Phase 1 / 2 study to assess the safety , efficacy , and pharmacokinetics of barasertib ( AZD 1152 ) in patients with advanced acute myeloid leukemia

P. Sonneveld, H. Kantarjian, G. Martinelli, 2011 .

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.

M. Andreeff, M. Sznol, G. Garcia-Manero, 2006, Leukemia research.

The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells

Z. Estrov, D. Harris, H. Kantarjian, 2011, Investigational New Drugs.

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

H. Kantarjian, J. Cortes, M. Talpaz, 2004, Cancer.

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.

Z. Estrov, H. Kantarjian, J. Cortes, 2009, Blood.

Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Is acute myeloid leukemia a liquid tumor?

Z. Estrov, G. Garcia-Manero, J. Cortes, 2013, International journal of cancer.

Results of triple therapy with interferon‐alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2003, Cancer.

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.

R. Kurzrock, H. Kantarjian, G. Garcia-Manero, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2016, American journal of hematology.

Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012, Cancer.

of early complete and major cytogenetic responses positive chronic myelogenous leukemia: high incidence - chromosome Imatinib mesylate therapy in newly diagnosed patients with Philadelphia

G. Garcia-Manero, J. Cortes, M. Talpaz, 2013 .

α chromosome-positive chronic myeloid leukemia after failure of interferon- Result of high-dose imatinib mesylate in patients with Philadelphia

G. Garcia-Manero, S. Verstovsek, E. Freireich, 2013 .

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

G. Daley, H. Kantarjian, G. Garcia-Manero, 2006, Cancer.

Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004, Leukemia research.

Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2003, Cancer.

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Blood.

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Blood.

Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2002, Blood.

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2009, Cancer.

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007, Cancer.

Pregnancy among patients with chronic myeloid leukemia treated with imatinib.

H. Kantarjian, J. Cortes, M. Talpaz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Responses in Patientswith ChronicMyelogenous Leukemia in Chronic PhaseTreatedwith ImatinibMesylate

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2005 .

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007, Leukemia & lymphoma.

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.

H. Kantarjian, J. Cortes, S. Verstovsek, 2004, Blood.

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

H. Kantarjian, J. Cortes, M. Talpaz, 2001, Blood.

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia

E. Estey, H. Kantarjian, G. Garcia-Manero, 2002, Cancer Chemotherapy and Pharmacology.

Phase 1 study of anti-CD 33 immunotoxin HUM-195 / rGEL in patients with advanced myeloid malignancies

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2013, American journal of hematology.

Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013, Cancer.

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.

E. Estey, H. Kantarjian, J. Cortes, 2002, Blood.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.

M. Konopleva, Z. Estrov, H. Kantarjian, 2015, The Lancet. Oncology.

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.

H. Kantarjian, F. Ravandi, S. Pierce, 2011, Blood.

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.

F. Ravandi, D. DeAngelo, J. Lancet, 2018, Blood.

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2012, Clinical lymphoma, myeloma & leukemia.

Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Leukemia & lymphoma.

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience

M. Konopleva, H. Kantarjian, T. Kadia, 2014, Leukemia.

Central nervous system relapse in adults with acute lymphoblastic leukemia

H. Kantarjian, J. Cortes, S. O'brien, 2002, Cancer.

Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2012 .

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013 .

Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia

H. Kantarjian, G. Garcia-Manero, S. Pierce, 2009, Cancer.

Anthracycline dose intensification in adult acute lymphoblastic leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2010, Cancer.

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2013, American journal of hematology.

The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.

Z. Estrov, R. Kurzrock, T. Manshouri, 2002, Blood.

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia

Z. Estrov, R. Kurzrock, T. Manshouri, 2002 .

Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.

M. Kelner, H. Kantarjian, F. Ravandi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Clinical lymphoma, myeloma & leukemia.

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

G. Gordon, H. Kantarjian, G. Garcia-Manero, 2005, Clinical Cancer Research.

Phase1Study of ABT-751, a NovelMicrotubule Inhibitor, in Patients with Refractory HematologicMalignancies

G. Gordon, H. Kantarjian, G. Garcia-Manero, 2005 .

WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.

Z. Estrov, D. Harris, H. Kantarjian, 2007, Cancer research.

WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML).

Z. Estrov, D. Harris, W. Priebe, 2005, Anticancer research.

Survival is poorer in patients with secondary core‐binding factor acute myelogenous leukemia compared with de novo core‐binding factor leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2009, Cancer.

Phase II Study of Fludarabine, Cytarabine (Ara-C), Cyclophosphamide, Cisplatin and GM-CSF (FACPGM) in Patients With Richter's Syndrome or Refractory Lymphoproliferative Disorders

M. Andreeff, H. Kantarjian, J. Cortes, 2002, Leukemia & lymphoma.

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte‐macrophage–colony stimulating factor (GM‐CSF) alternating with methotrexate and cytarabine plus rituximab and GM‐CSF in patients with Richter syndrome or fludarabine‐refractory chroni

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias

E. Estey, H. Kantarjian, G. Garcia-Manero, 2004, Clinical Cancer Research.

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.

H. Kantarjian, G. Garcia-Manero, D. Steensma, 2019, The Lancet. Haematology.

Significance of myelofibrosis in early chronic‐phase, chronic myelogenous leukemia on imatinib mesylate therapy

H. Kantarjian, J. Cortes, C. Bueso-Ramos, 2005, Cancer.

The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia.

H. Kantarjian, S. O'brien, J. Burger, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody.

H. Kantarjian, J. Cortes, S. Verstovsek, 2013, Clinical lymphoma, myeloma & leukemia.

Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.

M. Ratain, R. Larson, S. Verstovsek, 2006 .

Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.

H. Kantarjian, J. Cortes, D. McConkey, 2011, Clinical lymphoma, myeloma & leukemia.

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Leukemia research.

Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, American journal of hematology.

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion

M. Keating, S. O'brien, J. Burger, 2014, Haematologica.

Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon‐α

H. Kantarjian, E. Freireich, M. Talpaz, 2000 .

Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia.

Z. Estrov, D. Harris, H. Kantarjian, 2003, Blood.

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

H. Kantarjian, J. Cortes, S. Verstovsek, 2009, Supportive Care in Cancer.

Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2004 .

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2011, Blood.

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Leukemia & lymphoma.

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2014, Cancer.

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Cancer.

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

R. Kurzrock, J. Cortes, M. Keating, 2003, Cancer.

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia

H. Kantarjian, J. Cortes, R. Luthra, 2012, Haematologica.

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) Is Active for Relapsed and Refractory Patients with CLL.

H. Kantarjian, J. Cortes, M. Keating, 2004 .

Chronic myelomonocytic leukaemia after platinum‐based therapy for non‐small cell lung cancer: case report and review of the literature

F. Khuri, S. Faderl, K. Kim, 2006, Journal of clinical pharmacy and therapeutics.

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.

R. Larson, H. Kantarjian, J. Cortes, 2003, Leukemia research.

Acute Myeloid Leukemia Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

myeloid leukemia (AML) in patients 50 years of age or older Clofarabine and cytarabine combination as induction therapy for acute

Z. Estrov, J. Cortes, S. Verstovsek, 2013 .

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients

H. Kantarjian, J. Cortes, T. Kadia, 2011, Haematologica.

Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease

H. Kantarjian, P. Allen, L. Medeiros, 2012, Cancer.

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia

E. Estey, H. Kantarjian, G. Garcia-Manero, 2010, Cancer.

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

J. Issa, H. Kantarjian, G. Garcia-Manero, 2009, Cancer.

At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells

Z. Estrov, D. Harris, S. Verstovsek, 2016, The Journal of Immunology.

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

M. Konopleva, M. Andreeff, H. Kantarjian, 2011, Haematologica.

Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy.

E. Burton, H. Kantarjian, G. Garcia-Manero, 2008 .

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

H. Kantarjian, M. Keating, S. O'brien, 2011, Blood.

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.

Z. Estrov, H. Kantarjian, J. Cortes, 2002, Leukemia research.

Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

M. Konopleva, Z. Estrov, H. Kantarjian, 2008 .

Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

G. Garcia-Manero, D. Steensma, P. Amrein, 2015 .

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2014, Clinical lymphoma, myeloma & leukemia.

Cause of death in patients with lower‐risk myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Cancer.

Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study

H. Kantarjian, G. Garcia-Manero, D. Steensma, 2016 .

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

H. Kantarjian, A. Tsimberidou, S. O'brien, 2007, Leukemia & lymphoma.

Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008 .

Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

J. Gabrilove, H. Kantarjian, S. Eckert, 2008 .

Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high‐risk myelodysplastic syndrome

J. Issa, H. Kantarjian, G. Garcia-Manero, 2007, British journal of haematology.

A phase 1‐2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndrome

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2011, Cancer.

Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy

J. Issa, H. Kantarjian, G. Garcia-Manero, 2008 .

Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML

E. Estey, J. Issa, H. Kantarjian, 2008 .

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013, Front. Oncol..

Highlights from the 2008 Meeting of the American Society of Hematology San Francisco, CA; December 6–9, 2008

J. Cortes, M. Shrader, S. Faderl, 2009 .

Phase 1 study of polyethylene glycol formulation of interferon a-2 B ( Schering 54031 ) in Philadelphia chromosome – positive chronic myelogenous leukemia

H. Kantarjian, J. Cortes, M. Talpaz, 2001 .

Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making

Z. Estrov, H. Kantarjian, M. Talpaz, 1999 .

Clinical Use of Clofarabine for Adults and Children with Leukemia

D. Reinhardt, N. Hijiya, S. Faderl, 2017 .

Drug Insight: emerging new drugs in the treatment of myelodysplastic syndromes

H. Kantarjian, S. Faderl, 2005, Nature Clinical Practice Oncology.

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities

J. Issa, H. Kantarjian, G. Garcia-Manero, 2009, Cancer.

The Heterogeneous Prognosis of Patients with Myelodysplastic Syndrome (MDS) and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS?.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2008 .

Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2005 .

Decitabine Low-Dose Schedule (100 mg/m2/Course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2004 .

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.

E. Estey, R. Kurzrock, H. Kantarjian, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of 9‐nitro‐camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006, Cancer.

Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities

E. Estey, M. Konopleva, Z. Estrov, 2010 .

A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, A. Quintás-Cardama, 2011 .

Outcome after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen for Adults with De Novo or Minimally Treated Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.

P. Venugopal, H. Kantarjian, G. Garcia-Manero, 2012, The Lancet. Oncology.

Final results of the phase II study of rabbit anti‐thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony‐stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2012, British journal of haematology.

Predicting survival of patients with hypocellular myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, A. Quintás-Cardama, 2012, Cancer.

Factors associated with outcome of secondary MDS and AML: Review of 2,182 patients at MDACC.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS).

H. Kantarjian, G. Garcia-Manero, A. Nadeem, 2009 .

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.

F. Ravandi, D. DeAngelo, J. Lancet, 2018, Blood.

Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2008 .

Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.

G. Garcia-Manero, G. Borthakur, S. Pierce, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Blood.

Hyper‐CVAD plus nelarabine in newly diagnosed adult T‐cell acute lymphoblastic leukemia and T‐lymphoblastic lymphoma

M. Konopleva, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology.

Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia

S. Faderl, Jamie L. Koprivnikar, J. Mccloskey, 2017, OncoTargets and therapy.

Modern treatment programs for adults with acute lymphoblastic leukemia

H. Kantarjian, F. Ravandi, S. Faderl, 2007, Current hematologic malignancy reports.

Phase I Study of Clofarabine Plus Idarubicin and Clofarabine Plus Idarubicin Plus Cytarabine (ARA-C) in Patients (PTS) with Relapsed and Primary Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloid Blast Phase of Chronic Myeloid Leukemia (CML).

E. Estey, H. Kantarjian, G. Garcia-Manero, 2004 .

A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia

M. Andreeff, M. Sznol, H. Kantarjian, 2004, Clinical Cancer Research.

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

F. Khuri, N. Ibrahim, H. Kantarjian, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of therapy‐related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Cancer.

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML).

J. Cortes, R. Stone, J. Lancet, 2019, Blood.

Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Therapeutic advances in hematology.

PEG‐IFN‐α‐2b therapy in BCR‐ABL–negative myeloproliferative disorders

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007, Cancer.

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

M. Sznol, H. Kantarjian, G. Garcia-Manero, 2005, Clinical Cancer Research.

Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2006 .

Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

M. Andreeff, H. Kantarjian, J. Cortes, 2004 .

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

Susan O'Brien, Jorge Cortes, Rajyalakshmi Luthra, 2005, Clinical Cancer Research.

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long‐term outcome of patients with early chronic myeloid leukemia in chronic phase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Cancer.

Survival beneﬁt with imatinib mesylate versus interferon- (cid:1) –based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2006 .

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007, Cancer.

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Cancer.

Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib.

G. Daley, H. Kantarjian, J. Cortes, 2004 .

A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2006 .

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

Susan O'Brien, Jorge Cortes, E. Estey, 2006, Cancer.

Clofarabine: Past, present, and future

H. Kantarjian, V. Gandhi, S. Faderl, 2007, Leukemia & lymphoma.

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Jorge Cortes, Guillermo Garcia-Manero, Gautam Borthakur, 2013, Blood.

Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B‐cell chronic lymphocytic leukemia

H. Kantarjian, T. Manshouri, M. Keating, 2003, Cancer.

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

Steven M Kornblau, Susan O'Brien, Jorge Cortes, 2004, Blood.

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

Z. Estrov, H. Kantarjian, J. Cortes, 2013, Blood.

ALL Therapy: Review of the MD Anderson Program

H. Kantarjian, Deborah A. Thomas, S. Faderl, 2008 .

General Approach to the Therapy of Adult Acute Lymphoblastic Leukemia

H. Kantarjian, S. Faderl, 2008 .

Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia

Susan O'Brien, Jorge Cortes, Guillermo Garcia-Manero, 2006, Cancer.

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, J. Cortes, 2016, American journal of hematology.

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.

K. Do, H. Kantarjian, G. Garcia-Manero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of Adults with Acute Lymphocytic Leukemia (ALL) with Second Salvage Therapy

H. Kantarjian, J. Cortes, G. Borthakur, 2008 .

Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience

Z. Estrov, H. Kantarjian, A. Vega-Ruiz, 2009, International journal of hematology.

Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy

E. Estey, H. Kantarjian, G. Garcia-Manero, 2003, Leukemia.

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

E. Estey, H. Kantarjian, G. Garcia-Manero, 2003, Cancer Chemotherapy and Pharmacology.

Discrepancy In Diagnosis of Myelodysplastic Syndrome (MDS) Between Referral and Tertiary Care Centers: Experience at MD Anderson Cancer Center (MDACC)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.

H. Kantarjian, S. Verstovsek, Xuelin Huang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized P hase I /II S tudy o f T roxacitabine C ombined W ith Cytarabine, I darubicin, o r T opotecan i n P atients W ith Refractory M yeloid L eukemias

E. Estey, H. Kantarjian, G. Garcia-Manero, 2003 .

A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL).

B. Cheson, T. Kipps, M. Keating, 2005 .

The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies

S. Faderl, A. Skarbnik, 2017, Therapeutic advances in hematology.

Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.

Z. Estrov, E. Shpall, P. Jain, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

Z. Estrov, M. Keating, S. O'brien, 2014, Blood.

Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia

M. Keating, S. O'brien, W. Wierda, 2014, Leukemia & lymphoma.

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.

Z. Estrov, M. Keating, S. O'brien, 2009, Blood.

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.

M. Keating, S. O'brien, W. Wierda, 2010, Leukemia research.

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)

H. Kantarjian, G. Garcia-Manero, T. Manshouri, 2010, British journal of haematology.

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

K. Coombes, L. Rassenti, T. Kipps, 2009, Blood.

Monoclonal antibodies in chronic lymphocytic leukemia

M. Keating, S. Faderl, A. Ferrajoli, 2006, Expert review of anticancer therapy.

Treatment algorithms in CLL

S. Faderl, 2005, Hematology.

Running title: Sorafenib in hematologic malignancies

M. Konopleva, M. Andreeff, H. Kantarjian, 2010 .

Relapsed and Refractory Acute Myeloid Leukemia

S. Faderl, 2014 .

Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.

E. Estey, B. Storer, D. Stirewalt, 2010 .

Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Therapy for Patients (pts) ≥ 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2005 .

Biphenotypic acute leukaemia: a case series

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007, British journal of haematology.

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.

J. Cortes, J. Kolitz, J. Lancet, 2021, Blood advances.

The developing role of clofarabine in acute leukemias

S. Faderl, 2009 .

Management of patients with systemic mastocytosis: Review of M. D. Anderson Cancer Center experience

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004, American journal of hematology.

Preliminary Results of Fixed-Dose Oral Clofarabine (CLO) In Patients Who Have Failed Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes (MDS)

H. Kantarjian, M. Sekeres, G. Roboz, 2010 .

Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies

G. Wilding, H. Kantarjian, G. Garcia-Manero, 2010 .

Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2004, Leukemia research.

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome.

J. Cortes, J. Pagel, C. Jung, 2020, Blood advances.

Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia

K. Do, H. Kantarjian, T. Manshouri, 2003, British journal of haematology.

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.

J. Dipersio, M. Sznol, H. Kantarjian, 2003, Leukemia research.

A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.

Z. Estrov, H. Kantarjian, J. Cortes, 2012, Clinical Lymphoma, Myeloma & Leukemia.

Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy.

H. Kantarjian, J. Cortes, E. Jabbour, 2013, Clinical lymphoma, myeloma & leukemia.

Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2008, Leukemia research.

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.

J. Cortes, J. Kolitz, J. Lancet, 2021, The Lancet. Haematology.

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

Kim-Anh Do, Susan O'Brien, Jorge Cortes, 2007, Blood.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Cancer.

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial

J. Cortes, J. Lancet, S. Faderl, 2022, Journal of Hematology & Oncology.

Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high‐risk myelodysplastic syndrome

H. Kantarjian, J. Cortes, F. Ravandi, 2010, Cancer.

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

G. Calin, K. Rezvani, Katrien Van Roosbroeck, 2016, Clinical Cancer Research.

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.

M. Keating, S. O'brien, J. Burger, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

J. Reuben, Bang‐Ning Lee, S. Kornblau, 2011, Blood.

Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

C. Cleeland, H. Kantarjian, G. Garcia-Manero, 2013 .

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Z. Estrov, M. Andreeff, H. Kantarjian, 2006 .

Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin (Daunoxome), and Dexamethasone (HyperCVXD) Regimen in Richter's Syndrome

H. Kantarjian, J. Cortes, M. Keating, 2001, Leukemia & lymphoma.

Salvage therapy using FLT3 inhibitors may improve long‐term outcome of relapsed or refractory AML in patients with FLT3‐ITD

Z. Estrov, M. Andreeff, H. Kantarjian, 2013, British journal of haematology.

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

Jorge Cortes, Guillermo Garcia-Manero, E. Estey, 2007, Blood.

Intravenous Voriconazole (IV-VORI) Prevents Invasive Fungal Infections (IFI) in Patients (pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS).

E. Estey, H. Kantarjian, S. Verstovsek, 2004 .

Combination of Ofatumumab and Lenalidomide In Patients with Relapsed Chronic Lymphocytic Leukemia: Initial Results of a Phase II Trial

Z. Estrov, H. Kantarjian, M. Keating, 2010 .

Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

H. Kantarjian, S. O'brien, S. Faderl, 2007 .

Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL).

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2005 .

Kit inhibitor APcK110 extends survival in an AML xenograft mouse model

Z. Estrov, D. Harris, H. Kantarjian, 2011, Investigational New Drugs.

Shift of immunoglobulin phenotypes in B-cell precursor cell lines.

Z. Estrov, S. Faderl, 2002, Leukemia research.

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.

H. Kantarjian, M. Keating, S. O'brien, 2011, Blood.

Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2007 .

Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007 .

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

Cytopenias in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib (SPRYCEL®): Clinical Features and Management, Including Outcome after Hematopoietic Growth Factor Therapy.

H. Kantarjian, G. Garcia-Manero, A. Quintás-Cardama, 2006 .

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Z. Estrov, J. Reuben, Hui Gao, 2008, Blood.

The evolving role of Alemtuzumab in management of patients with CLL

J. Byrd, J. Gribben, P. Venugopal, 2005, Leukemia.

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

F. Ravandi, D. DeAngelo, J. Lancet, 2015 .

A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2002, Haematologica.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

M. Minden, H. Kantarjian, F. Ravandi, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.

J. Gabrilove, M. Maris, H. Kantarjian, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy

H. Kantarjian, G. Garcia-Manero, D. Kontoyiannis, 2004, Cancer.

Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies

E. Estey, S. Verstovsek, S. O'brien, 2006, Antimicrobial Agents and Chemotherapy.

Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high‐risk myelodysplastic syndrome undergoing induction chemotherapy

E. Estey, H. Kantarjian, J. Cortes, 2004, Cancer.

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Blood.

hematopoietic malignancies -deoxycytidine (decitabine) in ' hypomethylating agent 5-aza-2 Phase 1 study of low-dose prolonged exposure schedules of the

J. Issa, Rajan Mannari, H. Kantarjian, 2013 .

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Jorge Cortes, Guillermo Garcia-Manero, Francis J Giles, 2004, Blood.

Results of a Phase I/II Study of the Combination of 5-aza-2′-Deoxycytidine (DAC) and Valproic Acid (VPA) in Patients (pts) with Leukemia.

G. Rosner, J. Issa, H. Kantarjian, 2004 .

Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

J. Issa, M. Andreeff, H. Kantarjian, 2003, Cancer.

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

J. Issa, Y. Oki, Z. Estrov, 2007, Blood.

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2013, Leukemia research.

Sapacitabine in acute myelogenous leukemia

S. Faderl, Jamie L. Koprivnikar, J. Mccloskey, 2015 .

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2006, Blood.

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome‐related burkitt lymphoma/leukemia

H. Kantarjian, J. Cortes, S. O'brien, 2002, Cancer.

untreated patients with chronic lymphocytic leukemia Prognostic nomogram and index for overall survival in previously

K. Do, H. Kantarjian, G. Garcia-Manero, 2013 .

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years

E. Estey, J. Issa, H. Kantarjian, 2008, Cancer.

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.

K. Do, H. Kantarjian, P. Mclaughlin, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

K. Baggerly, E. Estey, M. Konopleva, 2014, Clinical Cancer Research.

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of numerical variation in FMS‐like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

H. Kantarjian, R. Luthra, K. Patel, 2012, Cancer.

A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center

H. Kantarjian, M. Kroll, S. Faderl, 2014, Cancer medicine.

Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006, Cancer.

Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells

G. Calin, Z. Estrov, D. Harris, 2013, Molecular Cancer.

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

B. Cheson, T. Kipps, M. Keating, 2009, Blood.

Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high‐dose cytarabine and idarubicin

M. Konopleva, M. Andreeff, H. Kantarjian, 2012, Cancer.

Adult acute lymphoblastic leukemia.

H. Kantarjian, E. Jabbour, S. Faderl, 2005, Mayo Clinic proceedings.

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.

K. Do, H. Kantarjian, G. Garcia-Manero, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chronic myelogenous leukemia: A review and update of therapeutic strategies

Susan O'Brien, Jorge Cortes, Guillermo Garcia-Manero, 2003, Cancer.

B-Cell Precursor Cell Lines

Z. Estrov, S. Faderl, 2002 .

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

C. Steidl, F. Solé, M. L. Le Beau, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Blood.

Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Clinical Cancer Research.

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004, Clinical Cancer Research.

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome‐positive chronic myelogenous leukemia in the chronic phase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells.

Z. Estrov, D. Harris, B. Aggarwal, 2003, Blood.

Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high‐dose cytarabine chemotherapy

H. Kantarjian, F. Ravandi, S. Pierce, 2009, Cancer.

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

H. Kantarjian, S. O'brien, S. Faderl, 2011 .

Late relapses in acute myeloid leukemia: analysis of characteristics and outcome

H. Kantarjian, J. Cortes, F. Ravandi, 2010, Leukemia & lymphoma.

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome–positive chronic myelogenous leukemia treated with interferon‐α regimens for early chronic phase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Treatment of Philadelphia chromosome–positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon‐alpha‐2b and low‐dose cytosine arabinoside

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Concepts and Strategies

C. Pui, H. Kantarjian, W. Stock, 2010 .

Rituximab in relapsed or refractory hairy cell leukemia.

H. Kantarjian, J. Cortes, C. Bueso-Ramos, 2003, Blood.

Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2003, Leukemia research.

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

Michael Rytting, Jorge Cortes, Guillermo Garcia-Manero, 2006, Blood.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

G. Rosner, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

D. Berry, J. Issa, H. Kantarjian, 2010, Leukemia & lymphoma.

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

J. Issa, M. Andreeff, H. Kantarjian, 2005 .

Thalidomide therapy for myelofibrosis with myeloid metaplasia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006, Cancer.

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Blood.

Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) ≥ 60 Years (yrs).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2009 .

Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia

Z. Estrov, G. Garcia-Manero, J. Cortes, 2015, Leukemia & lymphoma.

Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.

H. Kantarjian, J. Cortes, T. Manshouri, 2003, Leukemia research.

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG‐GO) as front‐line regimen in patients with core binding factor acute myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, American journal of hematology.

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine‐based regimens

K. Do, H. Kantarjian, G. Garcia-Manero, 2006, Cancer.

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Blood.

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2002, Blood.

chronic myelogenous leukemia in blast phase positive - Imatinib mesylate (STI571) therapy for Philadelphia chromosome

G. Garcia-Manero, J. Cortes, S. O'brien, 2013 .

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Blood.

precursor B-lineage acute lymphoblastic leukemia Prognostic significance of CD 20 expression in adults with de novo

H. Kantarjian, J. Cortes, S. Verstovsek, 2009 .

Prognostic significance of CD 20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009 .

Treatment of core‐binding‐factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony‐stimulating factor results in improved event‐free survival

E. Estey, H. Kantarjian, G. Garcia-Manero, 2008, Cancer.

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

K. Do, H. Kantarjian, G. Garcia-Manero, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

J. Issa, M. Andreeff, H. Kantarjian, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial.

R. Collins, P. Hari, M. Maris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

H. Kantarjian, J. Cortes, F. Ravandi, 2012, The Lancet Oncology.

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high‐risk myelodysplastic syndrome, and myeloproliferative disorders

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

J. Issa, H. Kantarjian, F. Ravandi, 2008, Leukemia & lymphoma.

Combination therapy with arsenic trioxide, all‐trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia

E. Estey, H. Kantarjian, G. Garcia-Manero, 2007, Cancer.

Advances in the treatment of relapsed/refractory acute lymphoblastic leukemia: a case study compendium.

E. Jabbour, G. Roboz, D. Douer, 2014, Clinical advances in hematology & oncology : H&O.

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.

H. Kantarjian, J. Cortes, T. Kadia, 2014, Clinical lymphoma, myeloma & leukemia.

T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.

H. Kantarjian, F. Ravandi, M. Keating, 2007, Leukemia research.

Non‐Hodgkin lymphoma of the prostate

D. Weisenburger, P. Bierman, J. Vose, 2011, American journal of hematology.

Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

H. Kantarjian, P. Jain, F. Ravandi, 2016, British journal of haematology.

Eradication of minimal residual disease in hairy cell leukemia.

H. Kantarjian, S. Verstovsek, Xuelin Huang, 2006, Blood.

Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia

H. Kantarjian, J. Cortes, T. Manshouri, 2003, Cancer.

A Single Institution Respective Study of Tyrosine Kinase Inhibitor Cessation in Patients with Chronic Phase CML in MMR

S. Goldberg, S. Faderl, C. Howlett, 2015 .

Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, American journal of hematology.

Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2006, Leukemia research.

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.

E. Estey, Y. Oki, H. Kantarjian, 2006, Blood.

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

E. Estey, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

E. Estey, M. Konopleva, Z. Estrov, 2017, Blood.

Use of All-Transretinoic Acid (ATRA) + Arsenic Trioxide (ATO) To Eliminate or Minimize Use of Chemotherapy (CT) in Untreated Acute Promyelocytic Leukemia (APL).

E. Estey, H. Kantarjian, G. Garcia-Manero, 2004 .

Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia

E. Estey, H. Kantarjian, J. Cortes, 2003, British journal of haematology.

Chapter 59 – Clinical Manifestations and Treatment of Acute Myeloid Leukemia

H. Kantarjian, S. Faderl, 2017 .

Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.

J. Cortes, J. Kolitz, J. Lancet, 2020 .

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.

H. Kantarjian, J. Cortes, S. Verstovsek, 2007, British journal of haematology.

Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia Associated with Chromosome 5 Abnormalities.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007 .

Fludarabine, cyclophosphamide, and multiple‐dose rituximab as frontline therapy for chronic lymphocytic leukemia

Z. Estrov, M. Keating, S. O'brien, 2015, Cancer.

Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?

H. Kantarjian, J. Cortes, J. Manning, 2011, Current hematologic malignancy reports.

Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome

J. Issa, H. Kantarjian, G. Garcia-Manero, 2009, Bone Marrow Transplantation.

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

M. Keating, S. O'brien, W. Wierda, 2010, Cancer.

Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).

Z. Estrov, H. Kantarjian, J. Reuben, 2009 .

Treatment with Lenalidomide Has a Positive Immunomodulatory Effect in Patients with Chronic Lymphocytic Leukemia.

Z. Estrov, J. Reuben, Hui Gao, 2008 .

STAT-3 Activates NF-κB in Chronic Lymphocytic Leukemia Cells

Z. Estrov, D. Harris, M. Keating, 2011, Molecular Cancer Research.

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

G. Garcia-Manero, T. Kadia, M. Keating, 2009 .

Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

relapsed and refractory chronic lymphocytic leukemia Lenalidomide induces complete and partial remissions in patients with

Z. Estrov, J. Reuben, Hui Gao, 2013 .

Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

Z. Estrov, H. Kantarjian, S. Kornblau, 2008 .

CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p.

Z. Estrov, H. Kantarjian, M. Keating, 2008 .

A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2012, Clinical lymphoma, myeloma & leukemia.

Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath‐1H)‐based therapies

H. Kantarjian, G. Borthakur, M. Keating, 2007, Cancer.

Chronic myelogenous leukemia: update on biology and treatment.

H. Kantarjian, M. Talpaz, S. Faderl, 1999, Oncology.

Signal Transducer and Activator of Transcription (STAT)-3 Activates Nuclear Factor (NF)-κB in Chronic Lymphocytic Leukemia Cells

Z. Estrov, D. Harris, M. Keating, 2011 .

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

F. Ravandi, D. DeAngelo, J. Lancet, 2016 .

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

M. Konopleva, M. Maris, H. Kantarjian, 2016 .

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

Scott E. Smith, B. Wood, M. Maris, 2016 .

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Scott E. Smith, B. Wood, M. Maris, 2016 .

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

F. Ravandi, D. DeAngelo, J. Lancet, 2016 .

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.

Susan O'Brien, Jorge Cortes, Guillermo Garcia-Manero, 2006, Blood.

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

M. Konopleva, Z. Estrov, H. Kantarjian, 2008 .

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML

J. Lancet, S. Goldberg, G. Uy, 2022, Blood advances.

The Combination of Lenalidomide and Rituximab Induces Complete and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

Z. Estrov, H. Kantarjian, M. Keating, 2010 .

Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

M. Keating, S. O'brien, W. Wierda, 2010 .

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL.

M. Andreeff, H. Kantarjian, J. Cortes, 2006 .

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome

Wei Zheng, F. Ravandi, E. Jabbour, 2015, Leukemia & lymphoma.

The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL).

H. Kantarjian, S. O'brien, W. Wierda, 2006 .

Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML,

P. Venugopal, H. Kantarjian, G. Garcia-Manero, 2011 .

Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission

P. Thall, Z. Estrov, H. Kantarjian, 2002, British journal of haematology.

Lenalidomide Induces Complete and Partial Responses in Patients with Relapsed and Treatment-Refractory Chronic Lymphocytic Leukemia (CLL).

H. Kantarjian, J. Reuben, Bang‐Ning Lee, 2006 .

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

J. Lancet, S. Goldberg, G. Uy, 2020, Transplantation and Cellular Therapy.

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II Study of Dasatinib (SPRYCEL™) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2007 .

Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.

G. Mufti, H. Kantarjian, F. Ravandi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Activity of alemtuzumab in patients with CD52‐positive acute leukemia

G. Garcia-Manero, J. Cortes, S. Verstovsek, 2006, Cancer.

Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2005 .

The Synthetic Hest Shock Protein (Hsp) 90 Inhibitor EC141 Induces Degradation of the Bcr-Abl p190 Protein and Apoptosis of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Cells.

Z. Estrov, D. Harris, H. Kantarjian, 2007 .

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

Inotuzumab ozogamicin (CMC-544) compared to chemotherapy in patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): A retrospective comparison.

H. Kantarjian, F. Ravandi, E. Jabbour, 2013 .

Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin.

F. Ravandi, S. Faderl, 2006, Leukemia research.

Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy

A. Pettitt, O. Frankfurt, S. Faderl, 2009, Leukemia.

Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia.

L. Akard, A. Pecora, S. Goldberg, 2015, Journal of oncology practice.

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Hoang Q. Nguyen, P. Thall, E. Estey, 2015, Haematologica.

Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP)

M. Konopleva, E. Burton, H. Kantarjian, 2011 .

A Prognostic Model of Therapy-Related Myelodysplastic syndrome .

Z. Estrov, G. Garcia-Manero, J. Cortes, 2009 .

Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia.

Steven M Kornblau, Kevin R Coombes, K. Coombes, 2011, Blood.

STAT3-Activated GM-CSFRα Translocates to the Nucleus and Protects CLL Cells from Apoptosis

Z. Estrov, D. Harris, C. Bueso-Ramos, 2014, Molecular Cancer Research.

Genomics STAT 3-Activated GM-CSFR a Translocates to the Nucleus and Protects CLL Cells from Apoptosis

Z. Estrov, D. Harris, C. Bueso-Ramos, 2014 .

Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation?

H. Kantarjian, E. Freireich, M. Talpaz, 2000, Cancer.

Simultaneous homoharringtonine and interferon‐α in the treatment of patients with chronic‐phase chronic myelogenous leukemia

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2002, Cancer.

FCR-3 as Frontline Therapy for Patients with Chronic Lymphocytic Leukemia (CLL).

H. Kantarjian, C. Bueso-Ramos, M. Keating, 2005 .

Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

G. Garcia-Manero, F. Ravandi, M. Keating, 2005 .

Prediction model for mortality after intracranial hemorrhage in patients with leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, American journal of hematology.

Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Pilot experience with continuous infusion alemtuzumab in patients with fludarabine‐refractory chronic lymphocytic leukemia

M. Keating, S. O'brien, R. Lapushin, 2008, European journal of haematology.

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Blood.

Very long‐term follow‐up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy

Susan O'Brien, Jorge Cortes, H. Kantarjian, 2012, Cancer.

Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy

Z. Estrov, H. Kantarjian, J. Cortes, 2011 .

Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2011 .

Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

H. Kantarjian, J. Cortes, F. Ravandi, 2009 .

Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2012 .

Adapt ive Randomized Study of Idarubic in and Cytarabine Versus Troxaci tabine and Cytarabine Versus Troxaci tabine and Idarubic in in Untreated Pat ients 50 Years or Older With Adverse Karyotype Acute Myelo id Leukemia

D. Berry, E. Estey, J. Wathen, 2003 .

Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.

E. Estey, Z. Estrov, F. Appelbaum, 2005, Blood.

Pediatric-Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia.

H. Kantarjian, J. Cortes, T. Kadia, 2009 .

Outcome for Adolescents and Young Adults (AYA) with the Hyper-CVAD (with or without Rituximab) Regimens for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.

H. Kantarjian, J. Cortes, F. Ravandi, 2009 .

Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

M. Konopleva, Z. Estrov, H. Kantarjian, 2011 .

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

H. Kantarjian, F. Ravandi, W. Plunkett, 2011, Investigational New Drugs.

The Effect of Interleukin-11 (Oprelvekin, Neumega®) on Thrombocytopenia Associated with Tyrosine Kinase Inhibitors (TKI) in Patients with Chronic Myeloid Leukemia (CML).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006 .

Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2011 .

Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2013 .

Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) as Frontline Therapy for CLL: Results of a Phase 2 Study.

H. Kantarjian, M. Keating, S. O'brien, 2006 .

Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Rituximab Plus GM-CSF for Patients with Chronic Lymphocytic Leukemia.

H. Kantarjian, M. Keating, S. O'brien, 2005 .

Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

Significant Clinical Activity of the Combination of 5-Azacytidine, Valproic Acid and All-Trans Retinoic (ATRA) Acid in Leukemia: Results of a Phase I/II Study.

J. Issa, Z. Estrov, M. Andreeff, 2006 .

Phase I C linical a nd P harmacology S tudy o f C lofarabine i n Patients W ith S olid a nd H ematologic C ancers

F. Khuri, N. Ibrahim, H. Kantarjian, 2003 .

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

H. Kantarjian, J. Cortes, F. Ravandi, 2005 .

Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Z. Estrov, H. Kantarjian, M. Keating, 2011 .

Clofarabine Is Active in Myelodysplastic Syndrome (MDS).

H. Kantarjian, J. Cortes, W. Plunkett, 2006 .

Highly Phosphorylated FOXO3A Is An Adverse Prognostic Factor in Acute Myeloid Leukemia.

Nianxiang Zhang, M. Konopleva, G. Borthakur, 2009 .

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

F. Ravandi, D. DeAngelo, J. Lancet, 2015 .

Phase I Study of Triciribine Phosphate Monohydrate, a Specific Inhibitor of AKt Phosphorylation, in Adult Patients with Advanced Hematologic Malignancies.

Z. Estrov, H. Kantarjian, F. Ravandi, 2007 .

Hyper-CVAD P rogram i n B urkitt's-Type A dult A cute Lymphoblastic L eukemia

H. Kantarjian, J. Cortes, F. Cabanillas, 1999 .

Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities.

J. Gabrilove, H. Kantarjian, T. Kovacsovics, 2009 .

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Z. Estrov, H. Burris, K. Patel, 2004 .

Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML) with Prior Hypomethylating Agent (HMA) Exposure Who Achieved Remission

J. Cortes, J. Kolitz, G. Schiller, 2020 .

V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia

M. Levis, H. Erba, S. Faderl, 2020 .

Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia

Z. Estrov, J. Reuben, Hui Gao, 2011, Cancer.

Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukemia (ALL).

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

Phase I Studies

Farhad, M. Ratain, R. Larson, 2022 .

PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Prognostic significance of Tie‐1 protein expression in patients with early chronic phase chronic myeloid leukemia

H. Kantarjian, J. Cortes, T. Manshouri, 2002, Cancer.

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)

R. Garcia, N. Saba, K. Seiter, 2021, Leukemia & lymphoma.

Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia.

H. Kantarjian, S. Verstovsek, M. Keating, 2004, Leukemia research.

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2006 .

FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations

M. Konopleva, Z. Estrov, M. Andreeff, 2011 .

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Leukemia & lymphoma.

Outcome with the Hyper-CVAD and Rituximab Regimen in Burkitt (BL) and Burkitt-Like (BLL) Leukemia/Lymphoma.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.

H. Kantarjian, S. Verstovsek, J. Karp, 2006, Leukemia research.

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2004, Blood.

Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011 .

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

G. Rosner, H. Kantarjian, G. Garcia-Manero, 2008 .

A model for prediction of FLT3‐ITD and NPM1 (without FLT3‐ITD) positivity in patients with newly diagnosed acute myeloid leukaemia

E. Estey, S. Meshinchi, D. Stirewalt, 2013, British journal of haematology.

Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)

E. Estey, F. Appelbaum, H. Kantarjian, 2012 .

Acute Leukemias

E. Estey, H. Kantarjian, M. Dreyling, 2021, Handbook of Pediatric Hematology and Oncology.

Acute Leukemias

E. Estey, H. Kantarjian, M. Dreyling, 2021, Handbook of Pediatric Hematology and Oncology.

Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

Bone Marrow (BM) May be More Informative Than Peripheral Blood (PB) to Evaluate Minimal Residual Disease (MRD) During 1st and 2nd Year Follow up After First-line Fludarabine, Cyclophosphamide, and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL)

Z. Estrov, M. Keating, S. O'brien, 2014 .

Bone Marrow May Be More Informative Than Peripheral Blood To Evaluate Minimal Residual Disease During 1st and 2nd Year Follow Up After First-Line Fludarabine, Cyclophosphamide, and Rituximab For Chronic Lymphocytic Leukemia

Z. Estrov, M. Keating, S. O'brien, 2013 .

Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).

J. Issa, A. Yang, H. Kantarjian, 2006 .

Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

S. Goldberg, S. Faderl, Jamie L. Koprivnikar, 2017 .

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015 .

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2002, Blood.

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

H. Kantarjian, Xuelin Huang, M. Keating, 2012 .

Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

H. Kantarjian, Xuelin Huang, M. Keating, 2013 .

Sweet's syndrome in chronic lymphocytic leukemia associated with neutropenic fever and granulocyte colony stimulation factor

M. Thompson, S. Faderl, S. Dyson, 2006, American journal of hematology.

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Leukemia.

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2009 .

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

B. Barlogie, M. Dimopoulos, P. Sonneveld, 2009, Blood.

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2003, Blood.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.

Z. Estrov, H. Kantarjian, J. Cortes, 2009, Blood.

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.

Z. Estrov, H. Kantarjian, J. Cortes, 2009, Blood.

Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (MDS).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007 .

In Vivo Response to Sequential Tyrosine Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) Modeled Based on In Vitro Properties of Particular BCR-ABL Kinase Domain (KD) Mutations.

Z. Estrov, H. Kantarjian, J. Cortes, 2007 .

Plausibility of Delaying Induction Therapy in Untreated AML.

P. Thall, E. Estey, H. Kantarjian, 2004 .

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

E. Estey, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013, Cancer.

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

H. Kantarjian, J. Cortes, F. Ravandi, 2012, The Lancet. Oncology.

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

K. Baggerly, E. Estey, M. Konopleva, 2014, Clinical Cancer Research.

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014, Leukemia & lymphoma.

K. Coombes, L. Rassenti, T. Kipps, 2009, Blood.

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

M. Konopleva, M. Andreeff, H. Kantarjian, 2011, Haematologica.

Prognostic impact of CD20 and CD25 expression in patients with Philadelphia-positive (Ph + ) acute lymphoblastic leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2010 .

Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL).

H. Kantarjian, J. Cortes, F. Ravandi, 2009 .

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

Impact of Imatinib Mesylate Dose Escalation on Resistance and Sub-Optimal Responses to Standard-Dose Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML).

H. Kantarjian, J. Cortes, G. Borthakur, 2007 .

Rituximab in relapsed or refractory hairy cell leukemia.

H. Kantarjian, J. Cortes, C. Bueso-Ramos, 2003, Blood.

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion

M. Keating, S. O'brien, J. Burger, 2014, Haematologica.

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2009, Blood.

H. Kantarjian, J. Cortes, S. O'brien, 2002, Cancer.

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

J. Issa, Z. Estrov, H. Kantarjian, 2012, Leukemia.

Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2008 .

Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s).

J. Gabrilove, H. Kantarjian, S. Eckert, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.

E. Estey, H. Kantarjian, A. Advani, 2009, Blood.

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

P. Sonneveld, H. Kantarjian, G. Martinelli, 2011, Blood.

A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2007 .

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.

K. Do, H. Kantarjian, G. Garcia-Manero, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML).

M. Konopleva, M. Andreeff, H. Kantarjian, 2009 .

Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are ≥ 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.

J. Gabrilove, H. Kantarjian, S. Eckert, 2009 .

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

M. Konopleva, Z. Estrov, H. Kantarjian, 2009 .

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.

M. Keating, S. O'brien, J. Burger, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

H. Kantarjian, P. Jain, F. Ravandi, 2016, British journal of haematology.

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

G. Calin, K. Rezvani, Katrien Van Roosbroeck, 2016, Clinical Cancer Research.

Effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on relapse-free survival in patients with newly diagnosed core-binding factor acute myelogenous leukemia.

Z. Estrov, H. Kantarjian, J. Cortes, 2012 .

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2011 .

Chronic myelogenous leukemia: update on biology and treatment.

H. Kantarjian, M. Talpaz, S. Faderl, 1999, Oncology.

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Blood.

Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia

Z. Estrov, G. Garcia-Manero, J. Cortes, 2015, Leukemia & lymphoma.

The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia.

Z. Estrov, H. Kantarjian, J. Cortes, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia.

J. Gorcsan, J. Lancet, J. Boehmer, 2023, Journal of Clinical Oncology.

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

D. Berry, J. Issa, H. Kantarjian, 2010, Leukemia & lymphoma.

Antiapoptotic and Proapoptotic Signals in Acute Myeloid Leukemia Granulocyte-macrophage Colony-stimulating Factor (gm-csf) Induces

Z. Estrov, D. Harris, H. Kantarjian, 2022 .

Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study

E. Estey, M. Sorror, B. Sandmaier, 2018, Blood.

Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.

E. Estey, H. Kantarjian, J. Cortes, 2012 .

A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2012, Clinical lymphoma, myeloma & leukemia.

Survival is poorer in patients with secondary core‐binding factor acute myelogenous leukemia compared with de novo core‐binding factor leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2009, Cancer.